Stryker cuts FY 2026 outlook after Q3 miss and operational setbacks
Stryker reported third‑quarter 2026 adjusted earnings of $3.52 per share and revenue of $6.52 billion, both below analyst expectations. The company lowered its full‑year organic net‑sales growth forecast to 6.5%‑7.0% and adjusted EPS guidance to $14.80‑$14.90, down from the prior range of 8.3%‑9.3% and $14.95‑$15.10. Management cited a slowdown in hip and knee procedures, supply constraints in the vascular business, a March cyber‑security incident and a July SAP rollout as the main drivers of the miss.
Why it matters
The guidance cut reduces the expected FY 2026 earnings per share, affecting valuation models that relied on the prior $14.95‑$15.10 range (see). The lower sales‑growth outlook also implies slower top‑line expansion for investors tracking Stryker’s growth trajectory.
Key facts
- 1Adjusted earnings per share for Q3 2026 were $3.52 (). finance.yahoo.com
- 2Q3 2026 revenue was $6.52 billion (). finance.yahoo.com
- 3Full‑year organic net‑sales growth guidance was revised to 6.5%‑7.0% (). quiverquant.com
- 4Full‑year adjusted EPS guidance was revised to $14.80‑$14.90 (). quiverquant.com
- 5Organic sales grew 7.7% year‑over‑year in Q3 (). finance.biggo.com
- 6MedSurg and Neurotechnology organic sales grew 9.1% in Q3 (). finance.biggo.com
Summary written by AlphAI AI Desk from 20 of 23 sources. Not investment advice. Figures are as stated by the linked sources.